Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

Several members of an FDA advisory committee warned on Monday that new data from studies on long-term use of opioids might ...

PTC Therapeutics announced Monday that its splicing drug for Huntington’s disease met the primary endpoint of a Phase 2 study ...

Function Health is buying Ezra in a bid to create a haven for people who want copious amounts of data on their bodies. The ...

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Deerfield Management is back with its third healthcare venture fund, this time securing more than $600 million to create new ...

FDA delays Stealth BioTherapeutics PDUFA date amid questions about agency disruption, while other companies like Sanofi and J ...

Not many would argue that Biotech is one of the riskiest industries on the globe. With costs hovering in the hundreds of millions of dollars, competitors ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

Flagship Pioneering has recruited Rahul Kakkar to lead its genetics-based drug discovery startup Quotient Therapeutics.